Beneficial effects of switching to denosumab from bisphosphonates or selective estrogen receptor modulators in postmenopausal women with type 2 diabetes and osteopenia/osteoporosis
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Diabetes Investigation"
DOI: 10.1111/jdi.13458
Abstract: Patients with type 2 diabetes mellitus have a higher bone fracture risk than patients without diabetes. Although denosumab (Dmab) is a potent bone resorption inhibitor, its efficacy in patients with type 2 diabetes mellitus has… read more here.
Keywords: selective estrogen; effects switching; denosumab; type diabetes ... See more keywords